PAPER Pirim D, Radwan ZH, Wang X, Niemsiri V, Hokanson JE, Hamman RF, Feingold E, Bunker CH, Demirci FY, Kamboh MI
SEARCH RESULTS
4168 RESULTS
PAPER Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ
Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.
J Clin Invest. 1986 Sep;78(3):722-8. PubMed: 3745433PAPER de Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais AD
The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
Arterioscler Thromb Vasc Biol. 1997 May;17(5):865-72. PubMed: 9157949PAPER Hsia SH, Connelly PW, Hegele RA
Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia.
J Investig Med. 1995 Apr;43(2):187-94. PubMed: 7735921PAPER Sinnott BP, Mazzone T
Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
Endocr Pract. 2006 Mar-Apr;12(2):183-7. PubMed: 16690468PAPER Abou Ziki MD, Strulovici-Barel Y, Hackett NR, Rodriguez-Flores JL, Mezey JG, Salit J, Radisch S, Hollmann C, Chouchane L, Malek J, Zirie MA, Jayyuosi A, Gotto AM Jr, Crystal RG
Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.
Am J Cardiol. 2014 Jan 15;113(2):302-8. Epub 2013 Oct 3 PubMed: 24239320PAPER Ji ZS, Fazio S, Mahley RW
Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
J Biol Chem. 1994 May 6;269(18):13421-8. PubMed: 8175773PAPER Hughes C, Choi ML, Yi JH, Kim SC, Drews A, George-Hyslop PS, Bryant C, Gandhi S, Cho K, Klenerman D
Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death.
Commun Biol. 2020 Feb 18;3(1):79. PubMed: 32071389PAPER Wei Y, Lu M, Mei M, Wang H, Han Z, Chen M, Yao H, Song N, Ding X, Ding J, Xiao M, Hu G
Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection.
Nat Commun. 2020 Feb 18;11(1):941. PubMed: 32071304PAPER Al-Dalahmah O, Sosunov AA, Shaik A, Ofori K, Liu Y, Vonsattel JP, Adorjan I, Menon V, Goldman JE
Single-nucleus RNA-seq identifies Huntington disease astrocyte states.
Acta Neuropathol Commun. 2020 Feb 18;8(1):19. PubMed: 32070434PAPER Jury N, Abarzua S, Diaz I, Guerra MV, Ampuero E, Cubillos P, Martinez P, Herrera-Soto A, Arredondo C, Rojas F, Manterola M, Rojas A, Montecino M, Varela-Nallar L, van Zundert B
Widespread loss of the silencing epigenetic mark H3K9me3 in astrocytes and neurons along with hippocampal-dependent cognitive impairment in C9orf72 BAC transgenic mice.
Clin Epigenetics. 2020 Feb 18;12(1):32. PubMed: 32070418PAPER Liu B, Liu J, Wang JG, Liu CL, Yan HJ
AdipoRon improves cognitive dysfunction of Alzheimer's disease and rescues impaired neural stem cell proliferation through AdipoR1/AMPK pathway.
Exp Neurol. 2020 May;327:113249. Epub 2020 Feb 15 PubMed: 32070713PAPER Marschallinger J, Altendorfer B, Rockenstein E, Holztrattner M, Garnweidner-Raith J, Pillichshammer N, Leister I, Hutter-Paier B, Strempfl K, Unger MS, Chishty M, Felder T, Johnson M, Attems J, Masliah E, Aigner L
The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
Neurotherapeutics. 2020 Feb 18; PubMed: 32072462PAPER Rodríguez-Losada N, de la Rosa J, Larriva M, Wendelbo R, Aguirre JA, Castresana JS, Ballaz SJ
Overexpression of alpha-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells.
J Adv Res. 2020 May;23:37-45. Epub 2020 Jan 22 PubMed: 32071790PAPER Wang XJ, Ma MM, Zhou LB, Jiang XY, Hao MM, Teng RK, Wu E, Tang BS, Li JY, Teng JF, Ding XB
Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy.
Nat Commun. 2020 Feb 18;11(1):934. PubMed: 32071315Current Filters
- Date Range : Nov 2019 to Feb 2020 x